Payment overview · 2025
General Payments
$28.17
1 reported records · 1 companies
Healthcare provider profile · identity verified
Gregory E Robinson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORTLAND, OR · NPI 1831151315
Verified facts
What the public records show
CMS Open Payments records show Gregory E Robinson, MD received $28.17 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.17 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $28.17 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 559 | 168 |
| Losartan Potassium | Losartan Potassium | 508 | 152 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 282 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 70 |
| Omeprazole | Omeprazole | 272 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 79 |
| Metformin Hcl | Metformin Hcl | 233 | 77 |
| Lisinopril | Lisinopril | 221 | 63 |
| Trazodone Hcl | Trazodone Hcl | 159 | 46 |
| Furosemide | Furosemide | 149 | 54 |
| Gabapentin | Gabapentin | 142 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 38 |
| Simvastatin | Simvastatin | 126 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 120 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 45 |
| Potassium Chloride | Potassium Chloride | 109 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 29 |
| Glipizide Er | Glipizide | 105 | 36 |
| Ozempic | Semaglutide | 104 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 28 |
| Buspirone Hcl | Buspirone Hcl | 85 | 27 |
| Eliquis | Apixaban | 84 | 27 |
| Finasteride | Finasteride | 83 | 31 |
| Warfarin Sodium | Warfarin Sodium | 82 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 20 |
| Tramadol Hcl | Tramadol Hcl | 72 | 36 |
| Alendronate Sodium | Alendronate Sodium | 65 | 18 |
| Bupropion Xl | Bupropion Hcl | 65 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Carvedilol | Carvedilol | 62 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 18 |
| Famotidine | Famotidine | 56 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 29 |
| Atenolol | Atenolol | 51 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 12 |
| Xarelto | Rivaroxaban | 49 | 14 |
| Allopurinol | Allopurinol | 47 | 14 |
| Clonidine Hcl | Clonidine Hcl | 45 | 15 |
| Prednisone | Prednisone | 44 | 26 |
| Sertraline Hcl | Sertraline Hcl | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | 15 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Torsemide | Torsemide | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 14 |
| Acyclovir | Acyclovir | 31 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 12 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 14 |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Naproxen | Naproxen | 20 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con 8 | Potassium Chloride | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28.17 · 1 records | ABBVIE INC. | CREON | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error